ASXL1 and myelodysplastic syndrome: Mutant ASXL1 has been implicated in modulating innate immunity by downregulating CLEC5 expression (a C-type lectin receptor activated by glycans), inhibiting myeloid differentiation. CLEC5 expression is notably diminished in MDS patients (15).